One Size Does Not Fit All™: Currax Pharmaceuticals launches new campaign to address emotional eating challenges faced by individuals seeking weight loss
Currax Pharmaceuticals LLC (“Currax”), a specialty biopharmaceutical company and manufacturer of the #1 oral weight loss medication brand CONTRAVE® (naltrexone HCl/bupropion HCl), proudly announced the launch of the brand’s new campaign, One Size Does Not Fit All™, which aims to demonstrate the unique challenges individuals who are overweight or suffering from obesity face and emphasizes the need for a personalized approach to weight loss to achieve long-term success.
Emotional eating impacts 40 to 50 percent of individuals who are overweight or suffering from obesity. It is defined as eating in response to positive or negative emotions. CONTRAVE is specifically designed to reduce hunger and control cravings, giving the patient control over their eating habits so they can lose weight and keep it off.
“Obesity is the number two preventable cause of death in the U.S. and has accelerated in prevalence as a result of the pandemic,” said George Hampton, President and CEO of Currax. “It is important that we recognize that weight loss is much more than eating less and moving more. A weight loss journey is a unique challenge for every individual, and a treatment like CONTRAVE can help to address it.”
A study out of the Mayo Clinic by Acosta, et al. and published in Obesity showed that 79 percent of patients lost more than 10 percent of their body weight in one year when following phenotype guided treatment versus 34 percent whose treatment was not phenotype guided. An individualized approach to medication selection can be key to patient success with obesity treatment.
Today, only 2 percent of individuals who are overweight or suffering from obesity are being treated with a prescription medicine. “Support for weight loss is not being discussed enough by patients and providers,” said Ed Cinca, SVP Global Marketing and Strategic Alliance Management at Currax. “Addressing unique challenges like emotional eating can help patients get the specific support they need to succeed.”
Currax is committed to increasing education around available treatment options, empowering patients to discuss their weight management challenges with their doctors and ensuring widespread access to weight-loss medications. Tackling the issues of convenience and affordability, Currax launched their CurAccess™ Program to all patients, regardless of insurance coverage, which allows patients to get their prescription of CONTRAVE for no more than $99 and free shipping.
CONTRAVE Important Safety Information and Indication
WHAT IS CONTRAVE?
CONTRAVE is a prescription weight-loss medicine that may help some adults with a body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off.
CONTRAVE should be used with a reduced-calorie diet and increased physical activity.
It is not known if CONTRAVE changes your risk of heart problems or stroke or of death due to heart problems or stroke.
It is not known if CONTRAVE is safe and effective when taken with other prescription, over-the-counter, or herbal weight-loss products.
CONTRAVE is not approved to treat depression or other mental illnesses, or to help people quit smoking (smoking cessation).
View additional important safety information in the Currax press release.
About Currax Pharmaceuticals LLC
Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on acquiring and commercializing prescription medicines worldwide. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), Treximet®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet®. For more information, please visit www.curraxpharma.com.
Source: Currax Pharmaceuticals/PR Newswire